Literature DB >> 25692112

In vivo Image of Cerebral Amyloid Angiopathy in an Alzheimer's Disease Mouse Model.

Jinho Kim1, Yong Jeong1.   

Abstract

Entities:  

Year:  2015        PMID: 25692112      PMCID: PMC4325644          DOI: 10.5853/jos.2015.17.1.87

Source DB:  PubMed          Journal:  J Stroke        ISSN: 2287-6391            Impact factor:   6.967


× No keyword cloud information.
Dear Sir: We would like to share an in vivo image of cerebral amyloid angiopathy (CAA) in an Alzheimer's disease (AD) mouse model. In AD, insoluble amyloid beta (Aβ) protein forms plaques in the parenchyma and also accumulates along the vessel walls.1 The Aβ usually accumulates in the tunica intima and tunica media layers of the vessels. CAA in AD is attributed to the failure of Aβ clearance from the brain through perivascular drainage pathways.2 In addition, CAA is thought to be responsible for the small vessel pathology that leads to ischemic changes in the white matter in AD. Thus, observation of CAA in regards to white matter lesions or other pathophysiology is important in understanding the development of AD. However, neuropathological studies have typically relied on sections from brain tissues at autopsy, which hampers understanding of the dynamics and topographic distribution of CAA. Cutting-edge optical techniques such as multi-photon laser scanning microscopy enable us to observe CAA in live animals in 3D.3 In this study, we used 7-month-old male APPswe/PS1ΔE9 transgenic mice (Jackson Laboratory). One day prior to imaging, methoxy-X04 (5 mg/kg; dissolved in 10% DMSO, 45% propylene glycol, and 45% phosphate-buffered saline) was injected intraperitoneally. This probe has been used for in vivo imaging of amyloid plaques in several studies.4,5 On the day of surgery, the mouse was anesthetized with ketamine and xylazine (0.12 mg/g and 0.01 mg/g, respectively), and a 2×2 mm craniotomy was made over the somatosensory area leaving the dura intact. The cortex was covered with 1% agarose and a glass cover slip. Texas Red-dextran (70 kDa, 100 µL, 5 mg/mL) was injected via the tail vein. All procedures were approved by the KAIST Institutional Animal Care and Use Committee (IACUC). We used a multi-photon laser scanning microscope (LSM510, Zeiss, Germany) and a tunable near-infrared femtosecond pulsed-laser (Chameleon II, Coherent, USA). Images were taken using a 20×objective lens (NA 1.0; Carl Zeiss) with a frame rate of 0.5-1 Hz. All images were obtained using the pulsed laser at an excitation wavelength of 800 nm. We discriminated between arterioles and venules based on the direction of red blood cell flow and the morphology of the vessels. As shown in the Figure 1 (and supplementary movie clip 1 for z-stack image), Aβ deposits were wrapped around the vessel wall in patches. Most plaques did not form complete rings forms at this stage. Seven months is still relatively young, and older mice would have dense Aβ deposits and complete ring forms of CAA. Interestingly, CAA was not observed in either the veins or the dura vessels.1 This finding supports the concept that CAA is formed by failure of Aβ elimination along the peri-arterial wall, but not along the peri-venous wall.6
Figure 1

Plaque and cerebral vessel imaging in an APPswe/PS1ΔE9 transgenic mouse (7-month-old; male). Methoxy-X04 (5 mg/kg) was injected intraperitoneally 1 day before the imaging session for plaque imaging. Texas Red-dextran (70 kDa) was injected intravenously on the day of imaging for vessel imaging. Imaging using two-photon laser scanning microscopy was performed up to a depth of 100 µm from the exposed dura. Amyloid aggregates (blue) are deposited on the cerebral arteriole wall (cerebral amyloid angiopathy; CAA) as well as in the brain parenchyma (amyloid plaques). CAA is not observed around the veins or dura vessels. (Red, cerebral blood vessel stained with Texas Red-dextran; a, arteriole; d, dura vessel; v, vein; arrowheads, amyloid plaques; scale bar=100 µm)

  6 in total

1.  Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative.

Authors:  William E Klunk; Brian J Bacskai; Chester A Mathis; Stephen T Kajdasz; Megan E McLellan; Matthew P Frosch; Manik L Debnath; Daniel P Holt; Yanming Wang; Bradley T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  2002-09       Impact factor: 3.685

2.  Amyloid-β-dependent compromise of microvascular structure and function in a model of Alzheimer's disease.

Authors:  Adrienne Dorr; Bhupinder Sahota; Lakshminarayan V Chinta; Mary E Brown; Aaron Y Lai; Keran Ma; Cheryl A Hawkes; JoAnne McLaurin; Bojana Stefanovic
Journal:  Brain       Date:  2012-10       Impact factor: 13.501

Review 3.  Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease.

Authors:  Roy O Weller; Malavika Subash; Stephen D Preston; Ingrid Mazanti; Roxana O Carare
Journal:  Brain Pathol       Date:  2008-04       Impact factor: 6.508

4.  Augmentation of sensory-evoked hemodynamic response in an early Alzheimer's disease mouse model.

Authors:  Jinho Kim; Yong Jeong
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

5.  Cerebral amyloid angiopathy: a systematic review.

Authors:  Alessandro Biffi; Steven M Greenberg
Journal:  J Clin Neurol       Date:  2011-03-31       Impact factor: 3.077

6.  Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease.

Authors:  Roy O Weller; Stephen D Preston; Malavika Subash; Roxana O Carare
Journal:  Alzheimers Res Ther       Date:  2009-10-12       Impact factor: 6.982

  6 in total
  2 in total

1.  Norvaline Restores the BBB Integrity in a Mouse Model of Alzheimer's Disease.

Authors:  Baruh Polis; Vyacheslav Gurevich; Michael Assa; Abraham O Samson
Journal:  Int J Mol Sci       Date:  2019-09-18       Impact factor: 5.923

2.  Cerebral amyloid angiopathy aggravates perivascular clearance impairment in an Alzheimer's disease mouse model.

Authors:  Shin Heun Kim; Ji Hoon Ahn; Hyunwoo Yang; Peter Lee; Gou Young Koh; Yong Jeong
Journal:  Acta Neuropathol Commun       Date:  2020-11-05       Impact factor: 7.801

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.